Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
about
Identification of an active reverse transcriptase enzyme encoded by a human endogenous HERV-K retrovirusRole of the DIS hairpin in replication of human immunodeficiency virus type 1Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acidsAggressive HIV-1?Structural basis for activation of α-boranophosphate nucleotide analogues targeting drug-resistant reverse transcriptaseMechanistic differences in RNA-dependent DNA polymerization and fidelity between murine leukemia virus and HIV-1 reverse transcriptasesA new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidineSelection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants.Optimal timing and duration of induction therapy for HIV-1 infectionDynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencingResistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysisHIV-1 Env C2-V4 diversification in a slow-progressor infant reveals a flat but rugged fitness landscapeHigh-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimenA second-site mutation that restores replication of a Tat-defective human immunodeficiency virusComparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C.Adaptation of HIV-1 depends on the host-cell environment.Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzeeMutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events.A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication.HIV-1 Transmission, Replication Fitness and Disease Progression.A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidineThe P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activitiesDecreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat.Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.Robust growth of human immunodeficiency virus type 1 (HIV-1)The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus.Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.An RNAi in silico approach to find an optimal shRNA cocktail against HIV-1.
P2860
Q24517809-C5DF72BA-6AC4-4ED9-BA51-63E1844D1B0BQ24680551-03707352-40ED-4067-8E86-D2B8C7815D48Q24682078-046275CF-545F-4412-AB3C-6A67910D4E4EQ24801219-51F016CE-9ADB-4BD0-8163-D4E3AA4215F4Q27625384-6234DDD9-C899-4992-AA86-57BAEEEC3A1EQ28302073-4054670E-483B-48EF-99C1-DA34ADB96E35Q28343476-387B3039-F410-4F8A-B125-E51E99E6F559Q28344137-8233A569-BEEE-4D4C-B1FD-E2BA9DF53A18Q28379497-D032E77D-0EC2-435E-91D6-42113505A331Q28469250-EEC3D2D0-01BE-4A0D-8161-77D34F30119DQ28474783-AEFA40AF-7A0B-43D0-9A5B-BEEF3AA324A4Q28478121-582D0218-08E1-4B51-AAA0-876244A8E401Q28487168-BB484B4F-B6A5-4C3D-AB4E-5096CB91FE1BQ28538692-FFC47EAD-681A-4CE8-9B02-5AB8FFB5304CQ30321811-26C6EEF2-52D9-46B2-87D8-CC5D23128CD5Q30394627-2267D45A-AE18-4E99-A9A0-A01469070D7BQ33277177-EA5E0F42-0EAB-491A-B9DF-D5C5526CB63AQ33442370-E92FBA3E-6FE7-4CC2-8A59-04BBE9CD5709Q33603586-3B31EB69-CB35-4725-A025-BB6ACECF262FQ33643192-79E33E64-3050-431E-81E5-EB40EDF1D160Q33724247-4DD7B94B-914A-47E1-92F9-52C0456B5C2EQ33737755-115852F8-E2A2-4FB7-8D2E-DBD4A178B8C3Q33743954-50C02718-FFB1-448B-9C48-4735EB435191Q33758570-6DA05DBA-7AC3-4BD0-9D6E-5624BBD4F606Q33782477-86E5529B-86EC-4466-86A5-14527DADA9F9Q33815628-2F6C08B1-5CB8-4B01-9931-5CDAB01CC6A7Q33820365-411E2FA7-5952-443E-A21A-4E151D58ED1DQ33826453-9940BB55-43E1-4B37-BA08-DCAF7A60AAD7Q33835795-07AF2C52-78A9-4751-B712-6D4637E836B4Q33838311-AEE47889-0D79-4F97-B409-F76D586C8E7BQ33843040-3CC1D1AF-1FBA-4EBC-A2EE-A7E5EDE76521Q33873983-4C13EB4A-6BA3-4FAC-A457-AAD1AAAC109DQ33906239-AB23599F-51F7-48A7-B5FE-07867A33850FQ34058254-C07815DF-C0A4-481D-80A7-B2422F60136BQ34334682-1769AE6A-B270-47B3-AD55-3CD88975680EQ34339657-CEA3A055-E391-492B-B77E-AD9E16F8AD52Q34351276-1B4FAE04-BE29-4F2B-B364-ACF226B84938Q34361509-7C5B170D-319B-4A3A-805E-210C3C1671F6Q34465037-977E32B3-7474-47A6-A4CC-9C0B50F78CD8Q34499103-5FD7C261-F8AB-42B0-901B-F0002CA64276
P2860
Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Reduced replication of 3TC-res ...... reverse transcriptase enzyme.
@ast
Reduced replication of 3TC-res ...... reverse transcriptase enzyme.
@en
type
label
Reduced replication of 3TC-res ...... reverse transcriptase enzyme.
@ast
Reduced replication of 3TC-res ...... reverse transcriptase enzyme.
@en
prefLabel
Reduced replication of 3TC-res ...... reverse transcriptase enzyme.
@ast
Reduced replication of 3TC-res ...... reverse transcriptase enzyme.
@en
P2093
P2860
P1433
P1476
Reduced replication of 3TC-res ...... e reverse transcriptase enzyme
@en
P2093
Berkhout B
Boucher CA
Oude Essink BO
van Gennip AH
van Kuilenburg AB
P2860
P304
P356
10.1002/J.1460-2075.1996.TB00777.X
P407
P577
1996-08-01T00:00:00Z